DNDi aims to deliver:

  • Deliver new, safer, more affordable, and effective treatments for people affected by Chagas disease.
  • Improve access to diagnosis and treatment using existing tools.

 

The current Chagas disease portfolio includes:

 Research

Discovery

Chagas C205 series
Chagas Hit-to-lead

Daiichi Sankyo Hit-to-lead
NTD Drug Discovery Booster Hit-to-lead
Screening

 Translation

Translation

Biomarkers 
Fexinidazole

Development

Development

New benznidazole regimens

 Implementation

Implementation

Benznidazole paediatric dosage forms

 

 

For more details on each project, see DNDi‘s Global Portfolio